Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

York Clinical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$972,433

1,272 payments

Through program year 2025, York Clinical Research, LLC is reported as receiving $972,433 in research payments, across 1,272 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $228,001 15
2024 Research $187,879 20
2023 Research $181,780 66
2022 Research $79,049 253
2021 Research $101,897 416
2020 Research $109,948 302
2019 Research $83,880 200

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novo Nordisk AS $346,466 1,082 payments
  2. AstraZeneca Pharmaceuticals LP $333,880 13 payments
  3. Novartis Pharmaceuticals Corporation $179,260 13 payments
  4. Merck Sharp & Dohme Corporation $108,832 161 payments
  5. Kowa Research Institute, Inc. $3,995 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. Ex9536-4388 $192,877 529 payments
  2. A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $139,047 1 payment
  3. Nn9535-4321 $114,926 422 payments
  4. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $106,345 5 payments
  5. Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $96,048 13 payments
  6. A Phase IIb Multicenter Randomised DoubleBlind Dose-inding Study to Evaluate the Efficacy Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria $74,142 2 payments
  7. A Randomized Double-Blind, Placebo-Controlled, Multicenter Trial Assessing the Impact of Lipoprotein (A) Lowering With Tqj230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease $50,932 4 payments
  8. A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event $45,975 1 payment
  9. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $34,841 2 payments
  10. Nn9924-4635 $34,063 53 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record